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reconstructive surgery of the breast- pregnancy:
diagnostic and therapeutic procedures in a
28 year old patient diagnosed with a tumor in
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Process of diagnostic procedures (oncological
approach)
Phase I: Primary diagnosis
1. Fine Needle Biopsy of tumor in left breast number
1666/2007- cellular neoplasm (september 2007).
2. Thick needle biopsy 4.10.2007- indeterminate
results.
Phase II: Surgical diagnoses
1. Quadrant resection of left mammary gland with
tumor (T2N0Mx) (October 12,2007) hisological pathol-
ogy number 14946 Infiltrative ductal carcinoma (8
points).
Receptor results in neoplastic cells of the tumor in the
left breast (October 12, 2007).
Receptors: Estrogen (+) Progesterone (-) Her2/Neu(-).
2. Lymphoscintography (October 25, 2007)- resection
of sentinel lymph node (using gamma camera lymph
node was located from the left axilla, where isotope was
located).
Histopahological results of the sentinel lymph node
showed reactive lymphadenitis.
Phase III: Diagnosis after surgery (genetic
approach)
Opolskie Center of Oncology ul. Katowicka 66a oraz
w MCND PUM w Szczecinie.
1. In family history BRCA 1 mutation in mother who
was during treatment of invasive carcinoma of the mam-
mary gland at that time.
2. Patients molecular results- BRCA1 mutation.
Phase IV: Diagnosis after genetic consultation
Gynecological exam, transvaginal ultrasound
(11.12.07).
Ultrasound of breast (11.12.07)- left mammary gland,
after surgical removal of tumor, neighboring fluid levels
0.4x3.27cm.
Marker CA-125- 11.5 U/ml (11.10.07).
MRI of breast (11.17.07)- neighboring with the surgi-
cal scar within left breast medially and anteriorly seen
fluid 2x2x2.2cm.
Treatment of patient in a patient with BRCA1 muta-
tion (oncological approach).
Qualified for Cis Platin chemotherapy (4 cycles of Cis
Platin- from November to February 2008) before
surgery.
Qualified for surgery (03.14.08) performed at the
oncological center in Gdansk, profilactic subqutanous
mastectomy of right breast, also subqutanous mastect-
omy of left breast (s.p. surgical removal of ductal ca.)
simultanously with reconstruction of both breasts.
After recontructive surgery of breasts patient was
under care of the Oncological Outpatient Clinic that is
part of “Latawiec” hospital in Swidnica.
Patient after treatment active in her career
Decision about pregnancy and medical consultation
(gynecological approach).
1. October 2009 patient decided to become pregnant
and 26 July 2010 had a healthy girl with Down Syn-
drome (kariotyp 47, XX,+21).
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but did not find a motive to terminate pregnancy.
3. Patient did not have amniocentesis. Program for
amnicentesis qualifies patients from age 35.
4. Patient during pregnancy and currently active in her
career.
Discussion
New element of oncological treatment was to decide if
the use Cis Platin before surgery was the right form of
treatment.
Resulted in a esthetic effect after reconstructive sur-
gery of breasts.
It was kept in mind that there could be negative
effects during pregnancy (hormonal changes) and after
pregnancy in patients gynecological health.
Patient was part of decision making throughout treat-
ment and possibilities of side effects in patient and the
child.
Results
Use of Cis Platin as a first choice together with surgical
treatment gives beneficial results in treatment of patient
with BRCA1 mutation.
It is not clear in what degree the treatment affected
the childs development during gestation.
Seems necessary that decides to get pregnant after
oncological treatment should undergo amnicentesis,
independent of patients age, to prevent possible terato-
genic effects in the development of the fetus.
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